In 2018, we continued to see a digital revolution in healthcare because of a wide range of technological advancements. From breakthroughs in cancer treatments to diagnostic devices powered by artificial intelligence (AI) and the increased adoption of Mobile Health Applications, we watched the development of many emerging digital health trends.
Last year was also a year that saw technology companies expand their healthcare reach through mergers and acquisitions. While we expect to see tech continue to transform the future of healthcare, it is anticipated to see more personalized care this year by customizing healthcare to a patient’s individual needs. As we continue to see new innovations emerge designed to improve a patient experience and overall health, there are several companies to take a closer look at.
XSport Global, Inc. (XSPT), a leading sports technology and media holding company focused on developing disruptive sports-centric technologies and related media projects, announced the rapid development of FitLinkDNA, which uses DNA-based health and wellness services to provide athletes with a digital blueprint of their genetic composition. This leads to the development of a tailored, personalized, wellness regimen the newest and most advanced way for athletes to train, compete and perform at their full capacity. The service is expected to be commercially available to consumers in early 2019 and will retail for $199.
XSport strategically acquired Head Trainer, Inc, the developer of the first sports-based app, endorsed by several athletes, to train the brain in the areas of focus and concentration, visual and spatial awareness, processing speed, memory and decision making. XSport acquired Shift Now, Inc, a full-service creative and digital marketing firm in September, which provides the company with full access to innovative approaches to marketing for Head Trainer and other holdings.
The company also announced entering into an equity purchase agreement up to $1,000,000 with TRITON FUNDS, LP. The fund’s founder Yash Thunkral stated, “We continue to seek out the best investment opportunities and XSport Global represents the type of early-stage, growth company we intend to add to our portfolio of investments”.
Microbot Medical Inc. (MBOT) announced receiving a notification from the European Patent Office that it will grant a patent for Application No. 08738207, which covers the Company’s ViRob™ technology platform. Including this latest notification, Microbot now has 30 issued/allowed patents and 18 patent applications pending worldwide.
“The allowance of this European patent application further strengthens our global intellectual property estate covering micro-robotic technology platform,” commented Harel Gadot, CEO, President and Chairman. “As we have demonstrated since becoming a publicly traded company, we are creating significant barriers to entry and this combined with the positive safety data we continue to achieve with our Self-Cleaning Shunt (SCS™), are reinforcing our pillars for success.”
The ViRobTM technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system with the ability to remain within the human body for prolonged time.
Valeritas Holdings, Inc., (VLRX) announced that its product V-Go is Preferred on the OptumRx formulary. V-Go is now available as Preferred on OptumRx formularies which include OptumRx Select, OptumRx Premium and OptumRx Core.
“We are very excited that V-Go is now Preferred on OptumRx formularies,” said CEO, John Timberlake. “V-Go helps patients simplify their insulin therapy and improve their management of diabetes. With this decision to make V-Go Preferred by OptumRx, V-Go should be even more affordable for many patients with type 2 diabetes.”
Valeritas is a medical technology company and manufacturer of wearable insulin deliver technologies. The company’s flagship product, V-Go Wearable Insulin Delivery Device which administers a continuous preset basal rate of insulin over 24 hours and provides discreet on-demand bolus dosing at mealtimes. V-Go is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients.
This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between MIDAM VENTURES, LLC and XSport Global, Inc., Midam was hired for a period from 11/4/2018 – 12/4/2018, which has been now been extended to 2/4/2019, to publicly disseminate information about XSport Global, Inc. including on the Website and other media including Facebook and Twitter. Midam was paid $50,000 (CASH) for & were paid “0” shares of restricted common shares. Midam own zero shares of XSport Global, Inc., which were purchased in the open market. Midam may buy or sell additional shares of XSport Global, Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer